Full Answer
Is zomedica the perfect stock for Growth Investors?
F ounded in 2013 and publicly-traded since 2016, Zomedica ( ZOM) is a relatively new organization. However, this veterinary-focused medical device company has seen tremendous interest among growth investors of late.
Is a cooling-off period in order for zomedica stock?
At nearly $3 per share, however, Zomedica's valuation became close to approximating the overall value of the entire global market. Accordingly, a cooling-off period appears to have been in order for this stock.
Is zomedica a buy for truforma?
Zomedica's self-installed Truforma platform is a little bigger than a toaster so veterinarians can provide results on their own without keeping clients waiting. At recent prices, Zomedica is still a small-cap stock with a market value of about $643 million at recent prices.
Will zomedica be a major player in the pet care market?
The sliver of the pet care market associated with diagnostic services is expected to reach $2.8 billion annually by 2024, and Zomedica has a plan to become a major player in this arena. This spring, the company intends to launch Truforma, a tool to help veterinarians detect adrenal and thyroid issues in dogs and cats.
Is Zomedica a good stock to buy now?
In the final analysis, ZOM stock is highly risky and best suited for speculative traders. Yet it's possible that retail traders will bid the stock up in 2022. And if they abandon Zomedica, it would be a dog-gone shame.
Should I sell my Zomedica stock?
Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding Zomedica Pharmaceuticals Corp is 'Strong Sell'.
Is ZOM expected to go up?
The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +430.74% increase from the last price of 0.23.
Why is Zomedica stock dropping?
The reason behind the decline goes back into the previous week, when Zomedica announced its third-quarter results after the market close on Nov. 12. The veterinary health company reported revenue in the third quarter of only $22,514. It posted a net loss of $6.3 million, or $0.091 per share.
Is Zomedica a real company?
About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.
Is Zomedica being shorted?
Short interest is the volume of Zomedica shares that have been sold short but have not yet been closed out or covered. As of May 31st, investors have sold 116,080,000 shares of ZOM short. 12.04% of Zomedica's shares are currently sold short. Learn More on Zomedica's current short interest.
What is Zomedica target price?
$1.20Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.25
Will Zomedica stock recover?
There is potential for a short term uptick in the Zom stock price, especially as the active weekly candle is mildly bullish. The relative strength index is relatively oversold and has been for quite some time. A mild divergence also supports the notion of a slight recovery in the Zom stock price in the near term.
Will Zomedica be delisted?
(NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.
Is Zomedica a pump and dump?
Zomedica Pharmaceuticals (NYSEMKT:ZOM) stock is the latest pump-and-dump looking to take investors for a ride.
Does ZOM reverse split?
Despite now generating revenue from the sale of its Truforma diagnostics system, Zomedica is valued at nearly 70 times Wall Street's projected sales for 2023. It's also nowhere near profitability. It's a strong candidate to enact a reverse split sometime over the next 12 to 18 months.
Is Luokung technology a buy?
The Luokung Technology Corp. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock.
Signals & Forecast
The Zomedica Pharmaceuticals Corp stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Support, Risk & Stop-loss
Zomedica Pharmaceuticals Corp finds support from accumulated volume at $0.36 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Zomedica Pharmaceuticals Corp stock A Buy?
Zomedica Pharmaceuticals Corp holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Insiders are very positive buying more shares than they are selling in Zomedica Pharmaceuticals Corp
In the last 100 trades there were 77.16 million shares bought and 11.3 million shares sold. The last trade was done 97 days ago by Powers Johnny D who bough 250 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Zomedica Pharmaceuticals?
Zomedica Corp. is a veterinary health company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica Corp., formerly known as Zomedica Pharmaceuticals Corp., is based in Ann Arbor, Michigan.
What is a strong weekly advance?
A strong weekly advance (especially when accompanied by increased volume) is a sought after metric for putting potential momentum stocks onto one's radar. Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) are strong.
